Multiple myeloma is the second most common haematological cancer in adults, reaching 1.8% of all neoplasms. Despite a dramatic improvement in the treatment, multiple myeloma is still an incurable disease with a median overall survival of five years. Therefore, new therapeutic approaches are needed to further improve outcomes, especially for high-risk myeloma that are often refractory, rapidly relapsing, and/or harbouring more aggressive features. Bispecific antibodies simultaneously target tumour cells and patient’s own effector immune cells, activating the latter close to the former leading to the killing of myeloma cells. Various targets on myeloma cells have been selected and are now part of clinical trials with very promising results. This review reports the latest data of the main ongoing studies and proposes a place for this new treatment in the large armamentarium against multiple myeloma.

(BELG J HEMATOL 2022;13(2):81–3)